Aprea Therapeutics, Inc.
APRE
$1.43
-$0.02-1.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 118.10K | 162.50K | 205.80K | 354.60K | 561.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 118.10K | 162.50K | 205.80K | 354.60K | 561.60K |
| Cost of Revenue | 1.91M | 2.48M | 2.36M | 2.85M | 2.56M |
| Gross Profit | -1.79M | -2.32M | -2.15M | -2.49M | -2.00M |
| SG&A Expenses | 1.59M | 1.77M | 1.07M | 1.61M | 1.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.51M | 4.25M | 3.43M | 4.45M | 4.41M |
| Operating Income | -3.39M | -4.09M | -3.23M | -4.10M | -3.85M |
| Income Before Tax | -3.24M | -3.93M | -2.89M | -3.78M | -3.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.24M | -3.93M | -2.89M | -3.78M | -3.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.24M | -3.93M | -2.89M | -3.78M | -3.47M |
| EBIT | -3.39M | -4.09M | -3.23M | -4.10M | -3.85M |
| EBITDA | -3.38M | -4.08M | -3.22M | -4.09M | -3.84M |
| EPS Basic | -0.53 | -0.66 | -0.49 | -0.64 | -0.58 |
| Normalized Basic EPS | -0.33 | -0.41 | -0.30 | -0.40 | -0.37 |
| EPS Diluted | -0.53 | -0.66 | -0.49 | -0.64 | -0.58 |
| Normalized Diluted EPS | -0.33 | -0.41 | -0.30 | -0.40 | -0.37 |
| Average Basic Shares Outstanding | 6.08M | 5.99M | 5.95M | 5.94M | 5.94M |
| Average Diluted Shares Outstanding | 6.08M | 5.99M | 5.95M | 5.94M | 5.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |